{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:12:06Z","timestamp":1776427926655,"version":"3.51.2"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"abstract":"<jats:p>Cytomegalovirus (CMV) infection increases morbidity in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Despite advancements in prevention and treatment, CMV reactivation remains a considerable concern following allo-HSCT. In this study, we aimed to evaluate the impact of CMV reactivation in allo-HSCT recipients on clinical outcomes and patient survival, as well as to identify the risk factors associated with CMV reactivation. This retrospective observational cohort study included data from 67 transplantations performed between 2019 and 2022 at a private hospital in Belo Horizonte, Brazil. Clinical, laboratory, and procedural data were collected. The median age of the patients was 47.0 years, and 52.2% of them were women. The most frequent indication for allo-HSCT was acute myeloid leukemia (28.4%), followed by myelodysplastic syndrome (16.4%). CMV reactivation occurred in 62.7% of the recipients, and the median time to CMV reactivation was 32.5 days. Six patients (9.0%) presented with CMV end-organ disease (83.3% were free of systemic disease); however, when present, gastrointestinal involvement was the most common disease (4.5%). In the multivariate analysis, the risk factors for CMV reactivation included acute lymphoblastic leukemia (P=0.006), mismatched human leukocyte antigen (HLA)-unrelated donors (P=0.002), and graft-versus-host disease (P=0.024). One-year overall survival was 57.7%. However, CMV reactivation was not significantly associated with mortality after controlling for confounding factors. CMV reactivation remains a common complication following allo-HSCT, with leukemia type, donor type, and graft-versus-host disease affecting the risk of disease recurrence. No direct correlation was observed between CMV recurrence and increased mortality or patient survival.<\/jats:p>","DOI":"10.1590\/1414-431x2026e15073","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:38:52Z","timestamp":1776425932000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the significance of cytomegalovirus reactivation in recipients of allogeneic hematopoietic stem cell transplantation: a cohort study"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2069-7381","authenticated-orcid":false,"given":"L.P. de","family":"Oliveira","sequence":"first","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais,  Brasil; Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-2004","authenticated-orcid":false,"given":"E.J.A.","family":"Paton","sequence":"additional","affiliation":[{"name":"Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1063-3149","authenticated-orcid":false,"given":"M.F.","family":"Giovanardi","sequence":"additional","affiliation":[{"name":"Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7002-7204","authenticated-orcid":false,"given":"A.F. da","family":"Silva","sequence":"additional","affiliation":[{"name":"Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1276","authenticated-orcid":false,"given":"L.G.","family":"Tavares","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-3463","authenticated-orcid":false,"given":"C.G.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8136-3140","authenticated-orcid":false,"given":"J.O.","family":"Dias","sequence":"additional","affiliation":[{"name":"Cancer Center Oncocl\u00ednicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-0666","authenticated-orcid":false,"given":"R.A.","family":"Fabreti-Oliveira","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais,  Brasil; Laborat\u00f3rio de Histocompatibilidade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"e29005","DOI":"10.1002\/jmv.29005","article-title":"Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: a narrative review","volume":"95","author":"Solano C","year":"2023","journal-title":"J Med Virol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern L","year":"2019","journal-title":"Front Microbiol"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"538.e1","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chor\u00e3o P","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.bbmt.2014.08.010","article-title":"Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review","volume":"20","author":"Sousa H","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"ref5","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2023-180305","article-title":"Late CMV disease after hematopoietic cell transplantation: significance of post-transplant cyclophosphamide, steroid treatment and CMV viral load","volume":"142","author":"Sadowska-Klasa A","year":"2023","journal-title":"Blood"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies","volume":"13","author":"Jakharia N","year":"2021","journal-title":"Curr Treat Options Infect Dis"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Science in medicine cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh M","year":"2011","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou G","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41409-023-01944-2","article-title":"CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality","volume":"58","author":"Eberhardt KA","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-010-0569-x","article-title":"Cytomegalovirus infection\/disease after hematopoietic stem cell transplantation","volume":"91","author":"Mori T","year":"2010","journal-title":"Int J Hematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern L","year":"2019","journal-title":"Front Microbiol"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00277-022-04841-8","article-title":"Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms","volume":"101","author":"Vallejo M","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia EJ","year":"2014","journal-title":"Cancer Lett"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski J","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Fatima A","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","article-title":"Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation","volume":"6","author":"Gerna G","year":"2006","journal-title":"Am J Transplant"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar D","year":"2009","journal-title":"Am J Transplant"},{"issue":"8","key":"ref18","first-page":"521.e1","article-title":"Cytomegalovirus infection post-allogeneic stem cell transplantation: experience from a country with high seropositivity","volume":"29","author":"Iftikhar R","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon MJ","year":"2010","journal-title":"Rev Med Virol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"e14083","DOI":"10.1111\/tid.14083","article-title":"Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: a systematic review","volume":"25","author":"Cho SY","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.htct.2018.10.004","article-title":"Cytomegalovirus disease in patients with hematopoietic stem cell transplantation, experience over 8 years","volume":"42","author":"Diaz L","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan ST","year":"2017","journal-title":"Blood Rev"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2003.11.010","article-title":"Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients","volume":"50","author":"Bonon SHA","year":"2005","journal-title":"J Infect"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/2279-042X.176554","article-title":"The risk factors for cytomegalovirus reactivation following stem cell transplantation","volume":"5","author":"Valadkhani B","year":"2016","journal-title":"J Res Pharm Pract"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00277-023-05509-7","article-title":"The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping","volume":"103","author":"Wu X","year":"2024","journal-title":"Ann Hematol"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George B","year":"2010","journal-title":"Transpl Infect Dis"},{"issue":"25","key":"ref27","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients","volume":"113","author":"Zhou W","year":"2009","journal-title":"Blood"},{"issue":"23","key":"ref28","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh M","year":"2009","journal-title":"Blood"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41409-018-0369-0","article-title":"Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation","volume":"54","author":"Yokoyama H","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni N","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"971156","DOI":"10.3389\/fimmu.2022.971156","article-title":"Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation","volume":"13","author":"Cui J","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-2143(99)90103-8","article-title":"Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus","volume":"134","author":"Visseren FL","year":"1999","journal-title":"J Lab Clin Med"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1002\/ajh.23998","article-title":"The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors","volume":"90","author":"Busca A","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","article-title":"New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Party of EBMT","volume":"58","author":"Cesaro S","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing A","year":"2018","journal-title":"Drugs"},{"issue":"19","key":"ref36","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele H","year":"2020","journal-title":"Blood"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program","volume":"26","author":"Robin C","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis","volume":"19","author":"Gim\u00e9nez E","year":"2019","journal-title":"Am J Transplant"},{"issue":"Supplement 1","key":"ref39","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2024-209164","article-title":"Letermovir prophylaxis reduces the risk of cytomegalovirus infection in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide","volume":"144","author":"Schmitz J","year":"2024","journal-title":"Blood"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/TP.0000000000004809","article-title":"Letermovir prophylaxis after kidney transplantation: another tool but not a revolution yet","volume":"108","author":"Roberts MB","year":"2024","journal-title":"Transplantation"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0100-879X2026000103829&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:39:00Z","timestamp":1776425940000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2026000103829&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S0100-879X2026000103829"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x2026e15073","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e15073"}}